非洲疾病预防控制中心的一名官员周四表示，针对本迪布焦（Bundibugyo）埃博拉病毒的候选疫苗正在乌干达进行新一阶段的临床试验，各方正继续努力遏制刚果民主共和国的疫情。
A candidate vaccine against the Bundibugyo Ebola virus is undergoing a new phase of clinical trials in Uganda, an official at the Africa Centers for Disease Control and Prevention said Thursday, as efforts continue to contain an outbreak in the Democratic Republic of Congo.
韦萨姆·曼库拉（Wessam Mankoula）在一次虚拟新闻发布会上表示，由牛津大学开发的ChAdOx1疫苗的Ib期试验于10月6日在乌干达启动。
Phase Ib trials of the ChAdOx1 vaccine, developed by the University of Oxford, began in Uganda on Oct. 6, Wessam Mankoula told a virtual news conference.
曼库拉作为埃博拉疫情应对大陆事件管理支持团队的负责人，透露Ia期试验已于7月在英国开始。
Mankoula, lead of the continental incident management support team for the Ebola response, said Phase Ia trials began in Britain in July.
他表示，由莫德纳（Moderna）开发的另一款候选疫苗最近已获得在乌干达进行Ib期试验的伦理批准，此前其Ia期试验已于8月在加拿大开始。
He said another candidate vaccine developed by Moderna recently received ethical approval for Phase Ib trials in Uganda after its Phase Ia trials began in Canada in August.
根据卫生部发布的最新更新，自疫情于5月宣布以来，刚果（金）已累计确诊埃博拉病例8,728例，其中死亡4,205例。
Congo has recorded 8,728 confirmed Ebola cases, including 4,205 deaths, since the outbreak was declared in May, according to the latest Health Ministry update.
最新疫情已波及七个省份：上韦莱省、伊图里省、北基伍省、南基伍省、下韦莱省、乔波省和南乌班吉省。
The latest epidemic has affected seven provinces: Haut-Uele, Ituri, North Kivu, South Kivu, Bas-Uele, Tshopo and South-Ubangi.
肯尼亚本周报告了首起输入性病例，患者在从刚果（金）旅行归来后死亡。
Kenya reported its first imported case this week involving a patient who died after traveling from Congo.
目前的疫情由本迪布焦埃博拉病毒引起，目前尚无获批的疫苗或疗法。
The current outbreak is caused by the Bundibugyo Ebola virus, for which no vaccine or treatment has been approved.
8月，刚果（金）从全球埃博拉病毒病疫苗库存中获配了70,000剂Ervebo疫苗，用于当前的疫情。该疫苗已被批准用于对抗扎伊尔埃博拉病毒。
In August, Congo was allocated 70,000 Ervebo vaccines from the global Ebola virus disease vaccine stockpile for use in the current outbreak. The vaccine is approved for use against the Zaire Ebola virus.
曼库拉称，迄今已有7,700多名医护人员和其他一线工作人员接种了疫苗。
More than 7,700 healthcare and other frontline workers have so far been vaccinated, Mankoula said.
流行病防范创新联盟（CEPI）于8月宣布与非洲生物制药公司Minapharm集团建立1650万美元的合作伙伴关系，以开发他们的本迪布焦候选疫苗。
The Coalition for Epidemic Preparedness Innovations announced in August a $16.5 million partnership with African biopharmaceutical company Minapharm Group to develop their Bundibugyo vaccine candidate.